CASE STUDY ANALYSIS

CASE STUDY ANALYSIS

Sources must be from no more than 5 years
Scenario:

A 49-year-old patient with rheumatoid arthritis comes into the clinic with a chief complaint of a fever.
Patient’s current medications include atorvastatin 40 mg at night, methotrexate 10 mg po every Friday morning and prednisone 5 mg po qam.
He states that he has had a fever up to 101 degrees F for about a week and admits to chills and sweats.
He says he has had more fatigue than usual and reports some chest pain associated with coughing.
He admits to having occasional episodes of hemoptysis.
He works as a grain inspector at a large farm cooperative.
After extensive work-up, the patient was diagnosed with Invasive aspergillosis.

 

The Assignment

(1- to 2-page case study analysis-this does not include title page and reference page)

Develop a 1- to 2-page case study analysis in which you:

Explain why you think the patient presented the symptoms described. (Not a trick question but reflective of a patient on immunosuppressive drugs and a high-risk employment for exposure to Aspergillosis)
Identify the genes that may be associated with the development of the disease.
Explain the process of immunosuppression and the effect it has on body systems.
Developing answers to these 3 questions, each question 1-2 paragraphs will bring you to the 2-page expected limit. 3 pages will not lose points but learning to synthesize points, provide current references (submissions like this would earn 3 primary references) and citations will garner full credit.

CASE STUDY ANALYSIS

Introduction

Compromised immune systems, such as those exposed to high-risk professions with Aspergillus spores or those receiving immunosuppressive medications, face substantial threats of contracting several fungal infections (Kochar et al., 2020). This case study analysis covers the case of a 49-year-old patient with rheumatoid arthritis who presents with fever as the chief complaint in the clinic. He takes atorvastatin 40 mg at night, methotrexate 10 mg, and prednisone 5 mg and works as a grain inspector. The paper tries to establish why he presents these symptoms, the genes involved, and the immunosuppression process, including its effects on the body system.

Why does the patient present the described symptoms

Invasive aspergillosis, a fungal infection from Aspergillus species, might be attributed to the patient’s symptoms. Several important variables caused the development of these particular symptoms in this patient. To treat his rheumatoid arthritis, the patient first takes immunosuppressive medications methotrexate and prednisone (Fürstenau et al., 2020). These drugs weaken the immune system’s capacity to fight off infections. Patients with weakened immune systems are more likely to develop invasive aspergillosis, making this patient more vulnerable to infection (Zoran et al., 2019).

In addition, the patient is at a high risk of exposure to Aspergillus spores due to their job as a grain inspector at a farm cooperative. Compost, grains, and rotting vegetation are popular places to find Aspergillus, whose pores can be spread through inhalation (Fürstenau et al., 2020). This job exposure greatly increases the likelihood of contact with the fungus. The patient’s symptoms, including fever, chills, sweats, exhaustion, chest pain with coughing, and sporadic hemoptysis, match up with typical Invasive aspergillosis signs. His medical history, professional risk factors, and these clinical signs and symptoms all strongly suggest that the immunosuppressive medicine and high-risk job played a role in developing this fungal infection.

Genes associated with the disease

Genetic variables that affect a person’s vulnerability to fungi infections may have a role in the development of invasive aspergillosis. Several genes have been linked to an elevated chance of acquiring the condition, notwithstanding the complexity and incomplete understanding of the genetic basis of susceptibility to Aspergillus infections (Zoran et al., 2019). The host’s immunological response, which is crucial in protecting against fungi like Aspergillus, is predominantly impacted by these genes. One of the main susceptibility genes, Dectin-1 (CLEC7A), codes for a receptor involved in identifying fungal cell wall elements. Dectin-1 variations can affect a person’s capacity to develop a successful immune response against Aspergillus (Zoran et al., 2019). Interleukin-10 (IL-10) and interferon-gamma (IFN-) cytokine genes, as well as polymorphisms in these genes, have been associated with altered immune responses that may increase susceptibility to fungal infections (Tolnai et al., 2020).

Additionally, genes related to the adaptive immune system, such as those in charge of T-cell regulation and activity, can affect susceptibility. These genes’ polymorphisms may impact the host’s capacity to manage and eliminate Aspergillus infections. While environmental factors, such as exposure to Aspergillus spores in the patient’s professional context, play a key part in disease development, it is vital to keep in mind that genetic traits, such as susceptibility, can also be influenced by environmental circumstances (Fürstenau et al., 2020).

Immunosuppression and its effects on the body system

Immunosuppression is the deliberate weakening of the immune system to stop it from mounting excessive immunological responses or attacking its tissues, usually through drugs or therapies. The impact of this process on many physiological systems is extensive. It primarily increases infection susceptibility by lowering immune cell production and function (Kochar et al., 2020). In the patient’s situation, rheumatoid arthritis drugs like methotrexate and prednisone impair immunological function, making them susceptible to Aspergillus infection. Additionally, immunosuppression increases cancer risk because it impairs the immune system’s capacity to recognize and destroy cancer cells. It may also result in delayed wound healing, an increased risk of developing chronic illnesses, and a decreased response to vaccines (Kochar et al., 2020). Immunosuppression is essential for treating some medical disorders, but it comes with a cost because it makes people more susceptible to infections and other health issues. After all, their immune systems are compromised.

Conclusion

In conclusion, compromised immune systems considerably increase the risk of fungal infections such as invasive aspergillosis, whether due to immunosuppressive drugs or high-risk occupational exposures. The case study of a 49-year-old patient with rheumatoid arthritis best illustrates this risk. His symptoms are consistent with this fungus, which is influenced by drug immunosuppression and occupational exposure from inspecting grains. An individual’s susceptibility to such infections is influenced by genetic variables, including genes related to immunological response and susceptibility. Effective diagnosis and treatment need to understand how genetics, immunosuppression, and environmental variables interact. While immunosuppression is important for some medical diseases, it comes with trade-offs such as increased cancer risk, delayed healing, and greater susceptibility to infections, highlighting the need to thoroughly examine all available options.

 

References

Fürstenau, M., Simon, F., Cornely, O. A., Hicketier, T., Eichhorst, B., Hallek, M., & Mellinghoff, S. C. (2020). Invasive aspergillosis in patients treated with ibrutinib. HemaSphere, 4(2).

Kochar, B., Cai, W., Cagan, A., & Ananthakrishnan, A. N. (2020). Pretreatment frailty is independently associated with an increased risk of infections after immunosuppression in patients with inflammatory bowel diseases. Gastroenterology, 158(8), 2104-2111.

Tolnai, E., Fidler, G., Szász, R., Rejtő, L., Nwozor, K. O., Biró, S., & Paholcsek, M. (2020). Free circulating mircoRNAs support the diagnosis of invasive aspergillosis in patients with hematologic malignancies and neutropenia. Scientific Reports, 10(1), 16532. https://www.nature.com/articles/s41598-020-73556-5

Zoran, T., Weber, M., Springer, J., White, P. L., Bauer, J., Schober, A., … & Löffler, J. (2019). Treatment with etanercept and low monocyte concentration contribute to the risk of invasive aspergillosis in patients post allogeneic stem cell transplantation. Scientific Reports, 9(1), 17231.